Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

464
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
464
Cancer Vaccines01:30

Cancer Vaccines

329
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
329

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phase I first-in-human dose-escalation trial of a bladder cancer-specific nanoparticle in non-muscle-invasive bladder cancer.

Nanomedicine (London, England)·2026
Same author

Long-term follow-up from the OMNIVORE trial: response-adaptive nivolumab and ipilimumab in advanced renal cell carcinoma.

Journal for immunotherapy of cancer·2026
Same author

Impact of Social and Structural Determinants of Health on Bladder Cancer Outcomes: Focus on Non-Muscle-Invasive Disease.

The Urologic clinics of North America·2026
Same author

Dementia and Frailty Impact Postoperative Care Trajectories and Burden among Older Adults Undergoing Radical Cystectomy for Bladder Cancer.

medRxiv : the preprint server for health sciences·2026
Same author

Genomic analysis of BCG unresponsive non-muscle-invasive bladder cancer identifies drivers of sensitivity to intravesical Gemcitabine/Docetaxel.

bioRxiv : the preprint server for biology·2026
Same author

A Phase I trial of PLZ4-coated paclitaxel-loaded micelles in patients with refractory non-muscle-invasive bladder cancer.

Nanomedicine (London, England)·2026

Related Experiment Video

Updated: May 28, 2025

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.2K

Examining Patient Characteristics in Bladder Cancer Clinical Trials Involving Immunotherapy.

Izuagie Ikhapoh1,2, Usomine Atairu3, Amanda Jane Reich4

  • 1Department of Medical Science, Harvard Medical School, Boston, MA 02115, USA.

Journal of Clinical Medicine
|February 13, 2025
PubMed
Summary

Clinical trials for bladder cancer (BC) using immune checkpoint inhibitors (ICIs) predominantly enroll Caucasian males aged 65+, highlighting potential underrepresentation of diverse patient groups.

Keywords:
and comorbiditybladder cancerdemographicsimmune checkpoint inhibitorrace

More Related Videos

An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

12.4K
Culture of Bladder Cancer Organoids as Precision Medicine Tools
08:39

Culture of Bladder Cancer Organoids as Precision Medicine Tools

Published on: December 28, 2021

4.5K

Related Experiment Videos

Last Updated: May 28, 2025

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.2K
An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

12.4K
Culture of Bladder Cancer Organoids as Precision Medicine Tools
08:39

Culture of Bladder Cancer Organoids as Precision Medicine Tools

Published on: December 28, 2021

4.5K

Area of Science:

  • Oncology
  • Clinical Trial Design
  • Immunotherapy

Background:

  • Understanding patient demographics in bladder cancer (BC) clinical trials is vital for effective trial design and interpreting research findings.
  • Immune checkpoint inhibitors (ICIs) represent a significant advancement in BC treatment, necessitating an analysis of the patient populations in relevant trials.

Purpose of the Study:

  • To analyze the demographic characteristics of patients enrolled in BC clinical trials that utilize ICIs.
  • To identify potential trends in patient representation and comorbidities within this trial population.

Main Methods:

  • A systematic review of publicly available data from BC clinical trials activated between 2013 and 2023.
  • Inclusion criteria focused on trials administering ICIs and reporting key survival endpoints (PFS, OS, DFS, EFS).
  • Exclusion of review articles and meta-analyses.

Main Results:

  • A total of 109 trials involving 8936 patients were analyzed.
  • The patient cohort was predominantly Caucasian (96%), with 23% identifying as female and 65% aged 65 or older.
  • Comorbidities like cardiovascular disease and diabetes were present in approximately 30% of patients and noted in one-third of trials.

Conclusions:

  • Recruitment strategies for BC trials involving ICIs should consider the impact of comorbidities on treatment efficacy.
  • Findings suggest potential underrepresentation of certain demographic groups in BC clinical trials, consistent with other reviews.
  • Further research into optimizing trial diversity is warranted to ensure generalizability of ICI treatment outcomes.